# Yong Song

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/yong-song/

## Facts

| Field | Value |
| --- | --- |
| Citations | 16,600 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 66 |
| i10-index | 283 |
| Last Known Institution | Nanjing University of Chinese Medicine |
| OpenAlex ID | https://openalex.org/A5100612794 |
| ORCID iD | https://orcid.org/0000-0003-4979-4131 |
| Works | 561 |

## Researcher papers

- [Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial](https://scholariq.org/papers/icotinib-versus-gefitinib-in-previously-treated-advanced-non-small-cell-lung/)
- [Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)](https://scholariq.org/papers/efficacy-and-safety-of-sintilimab-plus-pemetrexed-and-platinum-as-first-line/)
- [First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advancedEGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study](https://scholariq.org/papers/first-line-icotinib-versus-cisplatin-pemetrexed-plus-pemetrexed-maintenance/)
- [Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study](https://scholariq.org/papers/bevacizumab-plus-erlotinib-in-chinese-patients-with-untreated-egfr-mutated/)
- [Icotinib versus whole-brain irradiation in patients with EGFR -mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial](https://scholariq.org/papers/icotinib-versus-whole-brain-irradiation-in-patients-with-egfr-mutant-non-small/)
- [Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non–Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01)](https://scholariq.org/papers/toripalimab-plus-chemotherapy-for-patients-with-treatment-naive-advanced-non/)
- [Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial](https://scholariq.org/papers/efficacy-of-aumolertinib-hs-10296-in-patients-with-advanced-egfr-t790m-nsclc/)
- [PRC1 contributes to tumorigenesis of lung adenocarcinoma in association with the Wnt/β-catenin signaling pathway](https://scholariq.org/papers/prc1-contributes-to-tumorigenesis-of-lung-adenocarcinoma-in-association-with-the/)
- [Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial](https://scholariq.org/papers/tislelizumab-plus-platinum-and-etoposide-versus-placebo-plus-platinum-and/)
- [Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial](https://scholariq.org/papers/efficacy-safety-and-biomarker-analysis-of-ensartinib-in-crizotinib-resistant-alk/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Researcher university

- [Nanjing University of Chinese Medicine](https://scholariq.org/institutions/nanjing-university-of-chinese-medicine/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.